Advertisement

Cancer Causes & Control

, Volume 30, Issue 5, pp 489–499 | Cite as

Global patterns and trends in the incidence of non-Hodgkin lymphoma

  • Adalberto Miranda-FilhoEmail author
  • Marion Piñeros
  • Ariana Znaor
  • Rafael Marcos-Gragera
  • Eva Steliarova-Foucher
  • Freddie Bray
Original Paper

Abstract

Purpose

Despite an increasing understanding of the pathology and genetics of non-Hodgkin lymphoma (NHL), global reports on variations in the incidence of NHL remain limited in their number and scope.

Methods

To provide a situation analysis, national incidence estimates for NHL in 185 countries for the year 2018 were obtained from the GLOBOCAN database. We also used recorded incidence data from Cancer Incidence in Five Continents (CI5) plus for years of diagnosis 1980–2012 to examine temporal trends.

Results

NHL ranked as the 5th to 9th most common cancer in most countries worldwide, with almost 510,000 new cases estimated in 2018. Observed incidence rates of NHL 2008–2012 varied markedly by world region: among males, rates were highest among Israel Jews [age-standardized (world) rate of 17.6 per 100,000), Australia (15.3), US whites (14.5), Canada (13.7), and Portugal (13.3)]. Where data were available, most populations exhibited stable or slightly increasing incidence rates; in North America, parts of Europe, and Oceania the rising incidence rates were generally observed until the 1990s, with a stabilization seen thereafter.

Conclusion

Marked variations in NHL incidence rates remain in populations in each world region. Special attention should be given to further etiological research on the role of endemic infections and environmental exposures, particularly in Africa, Asia, and Latin America. To permit internationally comparable statistics, an equal focus on addressing the quality of hematological information in population-based registries is also warranted.

Keywords

Lymphoid neoplasms Non-Hodgkin lymphoma Population-based cancer registries Global epidemiology 

Notes

Acknowledgments

The work reported here was undertaken by Dr. Miranda-Filho during the tenure of an IARC Postdoctoral Fellowship, partially supported by the European Commission FP7 Marie Curie—Actions—People—co-funding regional, national, and international programmes (COFUND). We would like to thank the Directors and staff of the population-based cancer registries worldwide who compiled and submitted their data for the CI5 and GLOBOCAN projects used in this paper.

Compliance with ethical standards

Conflict of interest

The authors declare no competing interests.

Supplementary material

10552_2019_1155_MOESM1_ESM.docx (23 kb)
Supplementary material 1 (DOCX 23 KB)

References

  1. 1.
    Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries: global cancer statistics 2018. CA Cancer J Clin.  https://doi.org/10.3322/caac.21492 Google Scholar
  2. 2.
    Weltgesundheitsorganisation (2017). WHO classification of tumours of haematopoietic and lymphoid tissues, Revised 4th edn. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al (eds) World Health Organization classification of tumours. International Agency for Research on Cancer, Lyon, p 585Google Scholar
  3. 3.
    Armitage JO, Gascoyne RD, Lunning MA, Cavalli F (2017) Non-Hodgkin lymphoma. Lancet 390(10091):298–310CrossRefGoogle Scholar
  4. 4.
    CRUK (2018) Non-Hodgkin’s lymphoma statistics. 2012. Available from: http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/non-hodgkin-lymphoma. Accessed 21 Jan 2019
  5. 5.
    Boffetta P (2011) I. Epidemiology of adult non-Hodgkin lymphoma. Ann Oncol 22(Supplement 4):iv27–iv31CrossRefGoogle Scholar
  6. 6.
    Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M et al (2018) Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 391(10125):1023–1075CrossRefGoogle Scholar
  7. 7.
    Morton LM, Slager SL, Cerhan JR, Wang SS, Vajdic CM, Skibola CF et al (2014) Etiologic heterogeneity among non-Hodgkin lymphoma subtypes: the InterLymph Non-Hodgkin lymphoma subtypes project. J Natl Cancer Inst Monogr 2014(48):130–144CrossRefGoogle Scholar
  8. 8.
    Plummer M, de Martel C, Vignat J, Ferlay J, Bray F, Franceschi S (2016) Global burden of cancers attributable to infections in 2012: a synthetic analysis. Lancet Glob Health 4(9):e609–e616CrossRefGoogle Scholar
  9. 9.
    Shiels MS, Engels EA (2017) Evolving epidemiology of HIV-associated malignancies. Curr Opin HIV AIDS 12(1):6–11CrossRefGoogle Scholar
  10. 10.
    Gibson TM, Morton LM, Shiels MS, Clarke CA, Engels EA (2014) Risk of non-Hodgkin lymphoma subtypes in HIV-infected people during the HAART era: a population-based study. AIDS 28(15):2313–2318CrossRefGoogle Scholar
  11. 11.
    Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M et al (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012: Globocan 2012. Int J Cancer 136(5):E359–E386CrossRefGoogle Scholar
  12. 12.
    United Nations Development Programme (2017) Human development programme index (HDI). Available from: http://hdr.undp.org/en/content/human-development-index-hdi. Accessed 21 Sept 2018
  13. 13.
    WHO Global Health Observatory. Available from: http://www.euro.who.int/en/health-topics/disease-prevention/tobacco. Accessed 16 Sep 2018
  14. 14.
    Bray F, Colombet M, Mery L, Piñeros M, Znaor A, Zanetti R, Ferlay J (eds) (2017) Cancer incidence in five continents, Vol. XI (electronic version). International Agency for Research on Cancer, Lyon. Available from: http://ci5.iarc.fr. Accessed 20 Aug 2018
  15. 15.
    Bray F, Colombet M, Mery L, Piñeros M, Znaor A, Zanetti R, Ferlay J (eds) (2017) Cancer incidence in five continents plus, (time trends) (electronic version). International Agency for Research on Cancer, Lyon. http://ci5.iarc.fr/CI5plus/Default.aspx. Accessed 22 Sep 2018
  16. 16.
    WHO. World Health Organization (1995) International statistical classification of diseases and health-related problems - 10th Revision, 2nd edn [Internet]. Available from: http://apps.who.int/classifications/icd10/browse/2010/en. Accessed 17 May 2017
  17. 17.
    Segi M (1960) Cancer mortality for selected sites in 24 countries (1950–1957). Tohoku University School of Medicine, SendaiGoogle Scholar
  18. 18.
    Jensen OM, International Agency for Research on Cancer, World Health Organization, International Association of Cancer Registries (eds) (1991) Cancer registration: principles and methods, IARC scientific publications. International Agency for Research on Cancer, Lyon, p 288Google Scholar
  19. 19.
    R Development Core Team. R Development Core Team (2014) R: a language and environment for statistical computing (computer programme). R Foundation for Statistical Computing, ViennaGoogle Scholar
  20. 20.
    Østgård LSG, Nørgaard M, Nørgaard JM, Severinsen MT, Sengeløv H, Friis LS et al (2013) Data quality in the Danish national acute leukemia registry: a hematological data resource. Clin Epidemiol 5:335CrossRefGoogle Scholar
  21. 21.
    McKay P, Fielding P, Gallop-Evans E, Hall GW, Lambert J, Leach M et al (2016) Guidelines for the investigation and management of nodular lymphocyte predominant Hodgkin lymphoma. Br J Haematol 172(1):32–43CrossRefGoogle Scholar
  22. 22.
    Eichenauer DA, Thielen I, Haverkamp H, Franklin J, Behringer K, Halbsguth T et al (2014) Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: a report from the German Hodgkin study group. Blood 123(11):1658–1664CrossRefGoogle Scholar
  23. 23.
    IARC. IARC (1997) Epstein–Barr virus and Kaposi’s sarcoma herpesvirus/human herpesvirus 8. World Health Organization, Lyon. Available from: https://monographs.iarc.fr/iarc-monographs-volume-100b-epstein-barr-virus/. Accessed 10 Jan 2019
  24. 24.
    Weltgesundheitsorganisation, Swerdlow SH, International Agency for Research on Cancer (eds) (2008) WHO classification of tumours of haematopoietic and lymphoid tissues: [… reflects the views of a working group that convened for an Editorial and Consensus Conference at the International Agency for Research on Cancer (IARC), Lyon, October 25–27, 2007, World Health Organization classification of tumours, 4 edn. International Agency for Research on Cancer, Lyon. p 439Google Scholar
  25. 25.
    Castillo JJ, Beltran BE, Miranda RN, Young KH, Chavez JC, Sotomayor EM (2016) EBV-positive diffuse large B-cell lymphoma of the elderly: 2016 update on diagnosis, risk-stratification, and management: EBV+ DLBCL 2016 update. Am J Hematol 91(5):529–537CrossRefGoogle Scholar
  26. 26.
    Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R et al (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127(20):2375–2390CrossRefGoogle Scholar
  27. 27.
    Silverberg MJ, Lau B, Achenbach CJ, Jing Y, Althoff KN, D’Souza G et al (2015) Cumulative incidence of cancer among persons with HIV in North America: a cohort study. Ann Intern Med 163(7):507–518CrossRefGoogle Scholar
  28. 28.
    Chaabna K, Bray F, Wabinga HR, Chokunonga E, Borok M, Vanhems P et al (2013) Kaposi sarcoma trends in Uganda and Zimbabwe: a sustained decline in incidence?: trends of KS incidence in Zimbabwe and Uganda. Int J Cancer 133(5):1197–1203CrossRefGoogle Scholar
  29. 29.
    Parkin DM, Garcia-Giannoli H, Raphael M, Martin A, Katangole-Mbidde E, Wabinga H et al (2000) Non-Hodgkin lymphoma in Uganda: a case–control study. AIDS 14(18):2929–2936(CrossRefGoogle Scholar
  30. 30.
    Chihara D, Ito H, Matsuda T, Shibata A, Katsumi A, Nakamura S et al (2014) Differences in incidence and trends of haematological malignancies in Japan and the United States. Br J Haematol 164(4):536–545CrossRefGoogle Scholar
  31. 31.
    Engels EA, Cho ER, Jee SH (2010) Hepatitis B virus infection and risk of non-Hodgkin lymphoma in South Korea: a cohort study. Lancet Oncol 11(9):827–834CrossRefGoogle Scholar
  32. 32.
    Kim H, Shin AR, Chung HH, Kim MK, Lee JS, Shim J-J et al (2013) Recent trends in hepatitis B virus infection in the general Korean population. Korean J Intern Med 28(4):413–419CrossRefGoogle Scholar
  33. 33.
    Arisawa K, Soda M, Endo S, Kurokawa K, Katamine S, Shimokawa I et al (2000) Evaluation of adult T-cell leukemia/lymphoma incidence and its impact on non-Hodgkin lymphoma incidence in southwestern Japan. Int J Cancer 85(3):319–324CrossRefGoogle Scholar
  34. 34.
    Proietti FA, Carneiro-Proietti ABF, Catalan-Soares BC, Murphy EL (2005) Global epidemiology of HTLV-I infection and associated diseases. Oncogene 24(39):6058–6068CrossRefGoogle Scholar
  35. 35.
    Perry AM, Diebold J, Nathwani BN, MacLennan KA, Müller-Hermelink HK, Bast M et al (2016) Non-Hodgkin lymphoma in the developing world: review of 4539 cases from the international non-Hodgkin lymphoma classification project. Haematologica 101(10):1244–1250CrossRefGoogle Scholar
  36. 36.
    van Leeuwen MT, Turner JJ, Joske DJ, Falster MO, Srasuebkul P, Meagher NS et al (2014) Lymphoid neoplasm incidence by WHO subtype in Australia 1982–2006: lymphoid neoplasms in Australia 1982–2006. Int J Cancer 135(9):2146–2156CrossRefGoogle Scholar
  37. 37.
    Marcos-Gragera R, Pollán M, Chirlaque MD, Gumà J, Sanchez MJ, Garau I et al (2010) Attenuation of the epidemic increase in non-Hodgkin’s lymphomas in Spain. Ann Oncol 21(Suppl 3):iii90–iii96Google Scholar
  38. 38.
    Adamson P, Bray F, Costantini AS, Tao M-H, Weiderpass E, Roman E (2007) Time trends in the registration of Hodgkin and non-Hodgkin lymphomas in Europe. Eur J Cancer 43(2):391–401CrossRefGoogle Scholar
  39. 39.
    Clarke CA, Glaser SL (2002) Changing incidence of non-Hodgkin lymphomas in the United States. Cancer 94(7):2015–2023CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Section of Cancer SurveillanceInternational Agency for Research on CancerLyon CEDEX 08France
  2. 2.Epidemiology Unit and Girona Cancer Registry (UERCG), Oncology Coordination Plan, Department of Health, Autonomous Government of CataloniaCatalan Institute of Oncology (ICO), Girona Biomedical Research Institute (IDIBGI), University of GironaGironaSpain

Personalised recommendations